Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

TSC1/2 mutations define a molecular subset of HCC with aggressive behaviour and treatment implication

14 Dec 2016

Abstract excerpt

Objective We investigated the mutational landscape of mammalian target of rapamycin (mTOR) signalling cascade in hepatocellular carcinomas (HCCs) with chronic HBV background, aiming to evaluate and delineate mutation-dependent mechanism of mTOR hyperactivation in hepatocarcinogenesis. Design We performed next-generation sequencing on human HCC samples and cell line panel. Systematic mutational screening of mTOR...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to PI3K/AKT/mTOR signaling in cancer
Share to Polyomavirus and related diseases
Share to Tuberous Sclerosis Complex Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 27974549
DOI: 10.1136/gutjnl-2016-312734

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

TSC1/2 mutations define a molecular subset of HCC with aggressive behaviour and treatment implicationPMID 27974549Read ↗

Loss of Tuberous Sclerosis Complex 2 (TSC2) Is Frequent in Hepatocellular Carcinoma and Predicts Response to mTORC1 Inhibitor Everolimus.Semantic proximity Read ↗

Role of the Mammalian Target of Rapamycin Pathway in Liver Cancer: From Molecular Genetics to Targeted TherapiesSemantic proximity Read ↗

p53 haploinsufficiency and increased mTOR signalling define a subset of aggressive hepatocellular carcinomaSemantic proximity Read ↗

Rap_GAP Domain of TSC2 Contributes to Tumor Suppression Through mTOR Signaling in Human Hepatocellular Carcinoma.Semantic proximity Read ↗

Pre-S2 Mutant-Induced Mammalian Target of Rapamycin Signal Pathways as Potential Therapeutic Targets for Hepatitis B Virus-Associated Hepatocellular CarcinomaSemantic proximity Read ↗

mTOR Signaling: Roles in Hepatitis B Virus Infection and Hepatocellular CarcinomaSemantic proximity Read ↗

Occurrence of Biased mTOR Signaling in Hepatocellular CarcinomaSemantic proximity Read ↗

TSC1 involvement in bladder cancer: diverse effects and therapeutic implicationsSemantic proximity Read ↗

[he importance of mTOR hyperactivity and RICTOR amplification, and the associated targeted therapy possibilities in malignant tumours].Semantic proximity Read ↗

Activating JAK1 mutation may predict the sensitivity of JAK-STAT inhibition in hepatocellular carcinoma.Semantic proximity Read ↗

A diverse array of cancer-associated MTOR mutations are hyperactivating and can predict rapamycin sensitivity.Semantic proximity Read ↗

Loss of Pten synergizes with c-Met to promote hepatocellular carcinoma development via mTORC2 pathwaySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.